anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Traumatic brain injury (TBI): Repairs blood-brain barrier, arrests chronic neurodegeneration, and restores cognition even when administered one year post-injury. Hypoxic-ischemic encephalopathy: Neuroprotective via PI3K/AKT/GSK3β pathway. Alzheimer's disease models: Reverses tau phosphorylation, blood-brain barrier deterioration, oxidative stress, DNA damage, neuroinflammation; enhances neurogenesis and synaptic plasticity; achieves full cognitive recovery. Other models: Protects against ischemic stroke, optic nerve injury, intracerebral hemorrhage, and chemotherapy-induced peripheral neuropathy.
trans-splicing A form of RNA splicing in which different RNA transcripts, synthesized in separate transcription events, are spliced together into a single, continuous transcript. This contrasts with the more conventional "cis-splicing", where segments of the same transcript are excised or re-arranged.
In the final, Zverev defeated Flavio Cobolli in a five-set contest, his longest match of the tournament by duration and sets played. With his win, Zverev became the first German men's singles champion since Henner Henkel in 1937, ending an 89 year drought. He became the first German male to win a major since Boris Becker in 1996 and joined Michael Stich and Becker to become the third German men's singles player to win a Major. In addition, he became the first player, male or female, to win a Major with Type 1 diabetes. Zverev rejoined the tour in Halle, reaching the semifinals just dropping one set to Vit Kopřiva in the second round. He lost the semifinal match to eventual finalist Taylor Fritz despite winning the first set, extending his ongoing losing streak against the American since Wimbledon 2024 to seven consecutive losses. During the 2026 Wimbledon, Zverev reached back-to-back second weeks of a major, and after defeating this time Taylor Fritz in the quarterfinal, and Arthur Fery in the semifinal, he made it to his second consecutive appearance in a Grand Slam final.. In the final, he lost to Sinner in four sets. Zverev lost his second round match to Tallon Griekspoor at the National Bank Open in 3 sets, then lost his 4th round match at the Cincinnati Masters to Tommy Paul in 3 sets. During the 2026 US Open, Zverev entered as the first seed following Jannik Sinner's withdrawal due to a knee injury. He nearly suffered a first-round defeat, being 2 points away from losing to Lorenzo Sonego in the 4th set while down two sets to one, and serving at 4-5, 30-30.
Sources: en.wikipedia.org
Tramadol can have pharmacodynamic, pharmacokinetic, and pharmacogenetic interactions. Tramadol is metabolized by CYP2D6 enzymes which contributes to the metabolism of approximately 25% of all medications. Any medications with the ability to inhibit or induce these enzymes may interact with tramadol. These include common antiarrhythmics, antiemetics, antidepressants (sertraline, paroxetine, and fluoxetine in particular), antipsychotics, analgesics, and tamoxifen.- Due to tramadol's serotonergic effects, tramadol has the potential to contribute to the development of an acute or chronic hyper-serotonin state called serotonin syndrome when used concurrently with other pro-serotonergic medications such as antidepressants (SSRIs, SNRIs, tricyclics, MAOIs), antipsychotics, triptans, cold medications containing dextromethorphan, and some herbal products such as St. John's wort. Concurrent use of 5-HT3 antagonists such as ondansetron, dolasetron, and palonosetron may reduce the effectiveness of both drugs. Tramadol also acts as an opioid agonist and thus can increase the risk for side effects when used with other opioid and opioid-containing analgesics (such as morphine, pethidine, tapentadol, oxycodone, fentanyl, and Tylenol 3). Tramadol increases the risk for seizures by lowering the seizure threshold. Using other medications that lower seizure threshold – such as antipsychotic medications, bupropion (an anti-depressant and smoking cessation drug), and amphetamines – can further increase this risk.
While some early bird-like species may have already been arboreal as well (including dromaeosaurids) such as Microraptor) most non-avialan dinosaurs seem to have relied on land-based locomotion. A good understanding of how dinosaurs moved on the ground is key to models of dinosaur behavior; the science of biomechanics, pioneered by Robert McNeill Alexander, has provided significant insight in this area. For example, studies of the forces exerted by muscles and gravity on dinosaurs' skeletal structure have investigated how fast dinosaurs could run, whether diplodocids could create sonic booms via whip-like tail snapping, and whether sauropods could float.
=== Refresh frequency limits for HDR video === Color depth of 10 bpc (30 bit/px or 1.07 billion colors) is assumed for all formats in these tables. This color depth is a requirement for various common HDR standards, such as HDR10. It requires 25% more bandwidth than standard 8 bpc video. HDR extensions were defined in version 1.4 of the DisplayPort standard. Some displays support these HDR extensions, but may only implement HBR2 transmission mode if the extra bandwidth of HBR3 is unnecessary (for example, on 4K 60 Hz HDR displays). Since there is no definition of what constitutes a "DisplayPort 1.4" device, some manufacturers may choose to label these as "DP 1.2" devices despite their support for DP 1.4 HDR extensions. As a result, DisplayPort "version numbers" should not be used as an indicator of HDR support.
=== Pharmacokinetics === When administered orally, CBN demonstrates a similar metabolism to Δ9-THC, with the primary intoxicating metabolite being produced through a hydroxylation reaction that occurs in the liver. The active metabolite generated via this process is called 11-OH-CBN, which is around two times as potent as CBN, and has demonstrated activity as a weak CB2 antagonist. This metabolism starkly contrasts that of standard cannabis edibles in terms of potency, given that 11-OH-THC has been reported to have 10× the potency of Δ9-THC. Due to high lipophilicity and first-pass metabolism, there is low bioavailability of CBN and other cannabinoids following oral administration. CBN metabolism is mediated in part by CYP450 isoforms 2C9 and 3A4. The metabolism of CBN may be catalyzed by UGTs (UDP-glucuronosyltransferases), with a subset of UGT isoforms (1A7, 1A8, 1A9, 1A10, 2B7) identified as potential substrates associated with CBN glucuronidation. The bioavailability of CBN following administration via inhalation (e.g., smoking or vaporizing) is approximately 40% that of intravenous administration. A small study of six cannabis users found a highly variable half life of 32 ± 17 hours upon intravenous administration. Similar to CBD, CBN is metabolized by the CYP2C9 and CYP3A4 liver enzymes and thus the half-life is sensitive to genetic factors that effect the levels of these enzymes.
Sources: en.wikipedia.org
Although this model is recommended by the National Institute of Mental Health (NIMH), critics claim that it has the potential to create power struggles in an intimate relationship and may disrupt equal partnerships.
In Rolf Singer's classification of the Agaricales mushrooms, it is also the type species of section Boletus, a grouping of about 30 related boletes united by several characteristics: a mild-tasting, white flesh that does not change colour when exposed to air; a smooth to distinctly raised, netted pattern over at least the uppermost portion of the stem; a yellow-brown or olive-brown spore print; white tubes that later become yellowish then greenish, which initially appear to be stuffed with cotton; and cystidia that are not strongly coloured. Molecular analysis published in 1997 established that the bolete mushrooms are all derived from a common ancestor, and established the Boletales as an order separate from the Agaricales. The generic name is derived from the Latin term bōlētus "mushroom", which was borrowed in turn from the Ancient Greek βωλίτης, "terrestrial fungus". Ultimately, this last word derives from bōlos/βῶλος "lump", "clod", and, metaphorically, "mushroom". The βωλίτης of Galen, like the boletus of Latin writers like Martial, Seneca and Petronius, is often identified as the much prized Amanita caesarea. The specific epithet edulis in Latin means "eatable" or "edible".
When rock climbing, it is not safe to grab ledges or crevices without examining them first, as snakes are cold-blooded and often sunbathe atop rock ledges. In the United States, more than 40 percent of people bitten by snakes intentionally put themselves in harm's way by attempting to capture wild snakes or by carelessly handling their dangerous pets—40 percent of that number had a blood alcohol level of 0.1 percent or more. It is also important to avoid snakes that appear to be dead, as some species will roll over on their backs and stick out their tongue to fool potential threats. A snake's detached head can immediately act by reflex and potentially bite. The induced bite can be just as severe as that of a live snake. As a dead snake is incapable of regulating the venom injected, a bite from a dead snake can often contain large amounts of venom. Snakebite-proof gaiters can also be worn to help prevent snakebites. As many snakes have relatively small fangs, gaiters may provide a physical barrier that prevents the fangs from penetrating the skin of the lower legs.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.